




TTY Biopharm 4105

Operational Results Report



2025.05.27

Disclaimer

This presentation contains certain forward-looking statements.

These forward-looking statements may be identified by words such as 'believes', 'expects', 'anticipates', 'projects', 'intends', 'should', 'seeks', 'estimates', 'future' or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others:

- 1 pricing and product initiatives of competitors;
- 2 legislative and regulatory developments and economic conditions;
- 3 delay or inability in obtaining regulatory approvals or bringing products to market;
- 4 fluctuations in currency exchange rates and general financial market conditions;
- 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products;
- 6 increased government pricing pressures;
- 7 interruptions in production
- 8 loss of or inability to obtain adequate protection for intellectual property rights;
- 9 litigation;
- 10 loss of key executives or other employees; and
- 11 adverse publicity and news coverage.

TTY Biopharm cautions that this foregoing list of factors is not exhaustive. There may also be other risks that management is unable to predict at this time that may cause actual results to differ materially from those in forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. TTY Biopharm undertakes no obligation to update publicly or revise any forward-looking statements. Any statements regarding earnings growth is not a profit forecast and should not be interpreted to mean that TTY Biopharm's earnings or earnings per share for this year or any subsequent period will necessarily match or exceed published earnings or earnings per share forecasts of TTY Biopharm Company Limited.

01 Q1/2025 Operational Highlights



Strong Revenue Growth in Q1/2025 with Overseas Markets Expansion

Revenue Overview


✓ **Consolidated Revenue**
YoY growth +15% 14.6 billion



✓ **Consolidated Operating Profit**
YoY growth +33% 4.1 billion



✓ **EPS**
YoY growth +39% NT\$1.57




Market Development Highlights

- Cooperate with international pharmaceutical companies to develop new products and improve diversified medical treatment solutions.
- Vaccine sales continue to grow due to the high-quality vaccines to benefit the health of the people.
- Improve overseas inspection and registration of self-made domestic new drugs.


Sales of Oncology

(Unit: NT Mn)



Sales of Antibiotics

(Unit: NT Mn)



Q1/2025
Operational
Highlights

Q1/2025
Financial
Performance

2025 Outlook

Three Arrows of Operation with Outstanding Results

Q1/2025
Operational
Highlights

**Export
Difficulty
Generic Drugs**

Launch the Drug Licenses Submission Globally

- Regulatory submissions initiated in Vietnam, the Philippines, Australia, South America, and Saudi Arabia.
- Domestic self-made breast cancer targeted generic drug submitted registration in Vietnam in February.

Q1/2025
Financial
Performance

**License-in
International New
Drugs**

Access to Global Therapies

- TTY_B, a new ingredient & new drug for Lymphoma received drug license in January.
- Pexeda, a chemotherapy drug combined with targeted drug to extend product life cycle.
- Pomado expanded indication of multiple myeloma received license in February.

2025 Outlook

**Self-developed
New Drug**

Cross-Border Corporate Collaboration








- The public funded cell vaccines increased significantly in 2025 with a total of 790,000 doses.
- Collaborate again with Taiwan Roche on oral targeted drug.

Strengthened Supply Resilience

- Bobimixyn (Polymyxin B), the first antibiotics new drug launched to meet the needs of clinical second-line.
- First domestically produced lung cancer targeted therapy (TTY_A) enters international treatment protocol in Taiwan.

Product Pipeline: Self-develop, License-in, Cooperation


- Alliance with international partners to strengthen the advantage of the product portfolio
- Joint-develop specialty of generic drugs with international partners and expand overseas markets

Oncology	2025	2026	2027
TTY_B (Lymphoma)			
TTY_A (Lung Cancer NSCLC)			
Intensive Care	2025	2026	2027
TTY_2D (Skin tissue infections and bacteremia caused by Gram-positive bacteria)			
TTY_3T			
TTY_3D			
Specialty	2025	2026	2027
Lipo-AB (Liposomes) : EU			
OT2015 (Microspheres) : US			

• Note: those without marked are in Taiwan

Deploy Globally and Expand Overseas Market

- License-in/ collaboration/ **sales 130 drugs in 18 countries globally.**
- The export market will continue to grow and expand steadily, focusing on the development of the US and other major markets.
- Deepen cooperation with ASEAN markets, and sign MOUs with key hospitals in Vietnam market.



02 Q1/2025 Financial Performance



Q1/2025 Financial Performance

Operational Results Report

Q1/2025
Operational
Highlights

Q1/2025
Financial
Performance

2025 Outlook

Income Statement (Unit: NT Thousand, except EPS)	Q1/2025	Q1/2024	YoY %
Net Sales	1,458,850	1,273,605	15%
Operating Cost	(574,396)	(500,746)	15%
Gross Profit	884,454	772,859	14%
Gross Margin (%)	61%	61%	
Operating Expenses	(471,386)	(461,019)	2%
Operating Profit	412,145	309,901	33%
Operating Margin (%)	28%	25%	
Non-operating Income	103,451	58,153	78%
Profit before Tax	515,596	368,054	40%
Net Income (Consolidated)	408,082	294,726	38%
Net Margin (%)	28%	23%	
Net Profit Attributable to Owners of the Parent Company	391,096	280,771	
EPS (Unit : NTD)	1.57	1.13	


Q1/2025 Financial Performance

- YoY consolidated revenue was 58.9 billion, +15% due to the high growth of overseas markets and Intensive Care BU, and momentum of reinvestment.
- YoY consolidated operating gross profit at 61%, and it's about the same as the same period last year.
- Operating expenses increased 2% than last year same period by the marketing fee increased.
- Non-operating income increased by 78% due to the increase of the lawsuit with Inopha was settled out of court, and the first litigation settlement benefit was recognized.
- Net income after tax was 408 million, and the net profit attributable to owners of the parent company was 391 million, and EPS was NT\$1.57, representing a year-over-year increase of NT\$0.44.


Q1/2025 Steady Revenue Growth

Q1/2025 Revenue Breakdown Q1/2025 Revenue Growth

Product Category %



Revenue (NT Mn)



Q1/2025
Operational
Highlights


Q1/2025
Financial
Performance

2025 Outlook

03 2025 Outlook




Core Strategy and the Three Arrows are Implemented




Strengthen Global Deployment

Explore potential products and expand international market through **authorization, distribution, strategic cooperation and M&A.**




International Regulations

Understand the regulations in targeted markets and plan for the RA strategy and timeline to speed-up products launch.




R&D Potentials

Integrate key technologies to create and focus on specialty platforms (liposomes, microspheres) to speed-up product development.




Strengthen Local Clinical Collaborations

Over the past 3 years, we've partnered with leading medical teams to support breakthrough clinical research and generate local data that guides real-world drug use.



Optimize Manufacturing Processes

Construct and maintain PIC/S GMP management system to manufacture injection and oral drugs.



Expand Marketing and Sales Channels

Expand domestic and overseas channels to promote high quality and suitable pharmaceutical drugs, to fulfill the unmet needs of patients and market.